Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
NCT ID: NCT01216267
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2010-06-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
NCT02759718
Chromogranin A as Blood Marker in Cancer Patients
NCT03817866
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
NCT02586844
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
NCT02948946
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma
NCT01387724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lansoprazole
lansoprazole for 7 days
Lansoprazole
lansoprazole 30 mg HS x 7 days
lansoprazole
lanzoprazole 30 mg HS for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lansoprazole
lansoprazole 30 mg HS x 7 days
lansoprazole
lanzoprazole 30 mg HS for 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy
Exclusion Criteria
* prostate cancer
* kidney failure (estimated GF \< 30 mL/Min)
* heart failure
* chronic atrophic gastritis
* pregnancy
Healthy subjects:
* age below 18 or above 70 years
* taking any chronic medication (except OCP)
* prostate cancer
* kidney failure (estimated GFR \< 30 mL/min)
* heart failure
* pheochromocytoma
* islet cell tumors
* medullary thyroid cancer
* essential hypertension
* neurofibromatosis
* use of proton pump inhibitors
* chronic atrophic gastritis
* pregnancy
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Western Ontario, Canada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stanislaus H. van Uum
Principle investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stan Van Uum, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Western University, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
London Health Sciences Center and St. Joseph's Health Care
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSREB16279
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.